415 related articles for article (PubMed ID: 19963135)
1. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
2. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
Yang Y; Valera V; Sourbier C; Vocke CD; Wei M; Pike L; Huang Y; Merino MA; Bratslavsky G; Wu M; Ricketts CJ; Linehan WM
Cancer Genet; 2012; 205(7-8):377-90. PubMed ID: 22867999
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.
Linehan WM; Rouault TA
Clin Cancer Res; 2013 Jul; 19(13):3345-52. PubMed ID: 23633457
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
[TBL] [Abstract][Full Text] [Related]
5. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
[TBL] [Abstract][Full Text] [Related]
7. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.
Bardella C; El-Bahrawy M; Frizzell N; Adam J; Ternette N; Hatipoglu E; Howarth K; O'Flaherty L; Roberts I; Turner G; Taylor J; Giaslakiotis K; Macaulay VM; Harris AL; Chandra A; Lehtonen HJ; Launonen V; Aaltonen LA; Pugh CW; Mihai R; Trudgian D; Kessler B; Baynes JW; Ratcliffe PJ; Tomlinson IP; Pollard PJ
J Pathol; 2011 Sep; 225(1):4-11. PubMed ID: 21630274
[TBL] [Abstract][Full Text] [Related]
8. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.
Xie H; Valera VA; Merino MJ; Amato AM; Signoretti S; Linehan WM; Sukhatme VP; Seth P
Mol Cancer Ther; 2009 Mar; 8(3):626-35. PubMed ID: 19276158
[TBL] [Abstract][Full Text] [Related]
9. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry.
Chen YB; Brannon AR; Toubaji A; Dudas ME; Won HH; Al-Ahmadie HA; Fine SW; Gopalan A; Frizzell N; Voss MH; Russo P; Berger MF; Tickoo SK; Reuter VE
Am J Surg Pathol; 2014 May; 38(5):627-37. PubMed ID: 24441663
[TBL] [Abstract][Full Text] [Related]
10. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.
Bayley JP; Launonen V; Tomlinson IP
BMC Med Genet; 2008 Mar; 9():20. PubMed ID: 18366737
[TBL] [Abstract][Full Text] [Related]
11. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase.
Frezza C; Zheng L; Folger O; Rajagopalan KN; MacKenzie ED; Jerby L; Micaroni M; Chaneton B; Adam J; Hedley A; Kalna G; Tomlinson IP; Pollard PJ; Watson DG; Deberardinis RJ; Shlomi T; Ruppin E; Gottlieb E
Nature; 2011 Aug; 477(7363):225-8. PubMed ID: 21849978
[TBL] [Abstract][Full Text] [Related]
12. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
14. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.
Muller M; Guillaud-Bataille M; Salleron J; Genestie C; Deveaux S; Slama A; de Paillerets BB; Richard S; Benusiglio PR; Ferlicot S
Mod Pathol; 2018 Jun; 31(6):974-983. PubMed ID: 29410489
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma.
Vocke CD; Ricketts CJ; Merino MJ; Srinivasan R; Metwalli AR; Middelton LA; Peterson J; Yang Y; Linehan WM
Genes Chromosomes Cancer; 2017 Jun; 56(6):484-492. PubMed ID: 28196407
[TBL] [Abstract][Full Text] [Related]
16. Fumarate Mediates a Chronic Proliferative Signal in Fumarate Hydratase-Inactivated Cancer Cells by Increasing Transcription and Translation of Ferritin Genes.
Kerins MJ; Vashisht AA; Liang BX; Duckworth SJ; Praslicka BJ; Wohlschlegel JA; Ooi A
Mol Cell Biol; 2017 Jun; 37(11):. PubMed ID: 28289076
[TBL] [Abstract][Full Text] [Related]
17. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Sudarshan S; Pinto PA; Neckers L; Linehan WM
Nat Clin Pract Urol; 2007 Feb; 4(2):104-10. PubMed ID: 17287871
[TBL] [Abstract][Full Text] [Related]
19. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
20. Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.
Yang Y; Lane AN; Ricketts CJ; Sourbier C; Wei MH; Shuch B; Pike L; Wu M; Rouault TA; Boros LG; Fan TW; Linehan WM
PLoS One; 2013; 8(8):e72179. PubMed ID: 23967283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
